Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

TG Therapeutics drops single-agent TGR-1202 in mid-stage blood cancer study due to lack of efficacy, continues with U2 + Benda on significant treatment effect; shares slip 1% premarket

Published 08/10/2017, 08:45 AM
© Reuters. TG Therapeutics drops single-agent TGR-1202 in mid-stage blood cancer study due to lack of efficacy, continues with U2 + Benda on significant treatment effect; shares slip 1% premarket
TGTX
-
  • TG Therapeutics (NASDAQ:TGTX) eases 1% premarket, albeit on only 700 shares, on the heels of its announcement of results from a pre-planned interim analysis of its Phase 2b clinical trial, UNITY-NHL, assessing single-agent TGR-1202 and the triple combination of TG-1101 + TG-1202 + bendamustine in patients with treatment-resistant diffuse large B-cell lymphoma (DLBCL) who are ineligible for high-dose chemo or transplant.
  • The independent Data and Safety Monitoring Board (DSMB) recommended the termination of enrollment in the single-agent TGR-1202 arm due to lack of efficacy and to continue with the triplet therapy arm, called U2 + Benda.
  • Relapsed DLBCL patients receiving U2 + Benda showed a 100% response rate while half of the refractory DLBCL patients responded. It will be evaluated in the next phase of the trial.
  • UNITY-NHL is a Phase 2/3 study that should be completed in mid-2019.
  • Now read: TG Therapeutics, A Highly Undervalued Oncology Stock With Solid Later-Stage Trials And Excellent Early Stage Trial


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.